RETRACTION: Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial

Zhu, Xiaofei; Cao, Yangsen; Liu, Wenyu; Ju, Xingzhu; Zhao, Xianzhi; Jiang, Lingong; Ye, Yusheng; Jin, Gang; Zhang, Huojun

doi:10.1016/s1470-2045(21)00286-2

Cited by 56 publications

(35 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Research on I-SABR has progressed rapidly. A recent phase 2 randomized trial reported that SBRT plus pembrolizumab and trametinib was effective and safe in patients with locally recurrent pancreatic cancer ( 46 ); and another phase 2 randomized trial demonstrated that neoadjuvant durvalumab combined with SBRT for early-stage NSCLC was well tolerated and associated with a high pathologic response rate ( 47 ). However, a phase 2 randomized trial of unselected patients with metastatic head and neck squamous cell carcinoma reported no improvement in response with the addition of SBRT to nivolumab ( 48 ).…”

Section: Discussionmentioning

confidence: 99%

Bibliometric Analysis of the Top-Cited Publications and Research Trends for Stereotactic Body Radiotherapy

Liu

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveThis study aims to analyze the 100 most cited papers and research trends on stereotactic body radiotherapy (SBRT).MethodsWe used Web of Science to identify the 100 most frequently cited papers on SBRT on September 29, 2021 and extracted the following data: publication year, source title, country/region, organization, total citations, and average number of citations per year. The research type and research domain were classified independently by the authors. Then we carried out a bibliometric analysis to determine the trends in research on SBRT.ResultsThese 100 papers were cited a total of 26,540 times, and the median number of citations was 190 (range, 138-1688). “Stereotactic body radiation therapy for inoperable early stage lung cancer” by Timmerman et al. had the highest number of total citations (1688 times). International Journal of Radiation Oncology, Biology, Physics published the largest number of papers (37 papers), followed by Journal of Clinical Oncology (13 papers). The USA contributed the most papers (67 papers), followed by Canada (18 papers). Primary lung cancer (33 papers, 10,683 citations) and oligometastases (30 papers, 7,147 citations) were the most cited research areas.ConclusionsTo the best of our knowledge, this is the first bibliometric analysis of the most frequently cited papers on SBRT. Our results provide insight into the historical development of SBRT and important advances in its application to cancer treatment. Early-stage non–small-cell lung cancer and oligometastases were the most cited research areas in the top 100 publications on SBRT, and SBRT combined with immunotherapy was a hot topic in the past few years. This study is helpful for researchers to identify the most influential papers and current research hotspots on SBRT.

show abstract

Section: Discussionmentioning

confidence: 99%

Bibliometric Analysis of the Top-Cited Publications and Research Trends for Stereotactic Body Radiotherapy

Liu

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In 2021, a random trial presented that adding RT to pembrolizumab immunotherapy significantly increased responses and outcomes in patients with metastatic non-small-cell lung cancer (156). A pooled analysis of two randomized trials showed that SBRT and pembrolizumab combined with trametinib were a new potential treatment option for patients with locally recurrent pancreatic cancer following surgical resection (157). If the results of more and more clinical trials are positive, it will determine how best to integrate these models and optimize synergy.…”

Section: Prospects and Challenges Of Combined Immunotherapy With Radi...mentioning

confidence: 99%

Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment

Wang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Though single tumor immunotherapy and radiotherapy have significantly improved the survival rate of tumor patients, there are certain limitations in overcoming tumor metastasis, recurrence, and reducing side effects. Therefore, it is urgent to explore new tumor treatment methods. The new combination of radiotherapy and immunotherapy shows promise in improving therapeutic efficacy and reducing recurrence by enhancing the ability of the immune system to recognize and eradicate tumor cells, to overcome tumor immune tolerance mechanisms. Nanomaterials, as new drug-delivery-system materials of the 21st century, can maintain the activity of drugs, improve drug targeting, and reduce side effects in tumor immunotherapy. Additionally, nanomaterials, as radiosensitizers, have shown great potential in tumor radiotherapy due to their unique properties, such as light, heat, electromagnetic effects. Here, we review the mechanisms of tumor immunotherapy and radiotherapy and the synergy of radiotherapy with multiple types of immunotherapies, including immune checkpoint inhibitors (ICIs), tumor vaccines, adoptive cell therapy, and cytokine therapy. Finally, we propose the potential for nanomaterials in tumor radiotherapy and immunotherapy.

show abstract

“…Radiotherapy is one of the important methods for the treatment of PC, especially suitable for patients with advanced PC ( 137 ). Radiotherapy may enhance the release and absorption of tumor-associated antigens, thereby promoting the initiation of anti-tumor T cells, and enhancing entry into the tumor due to the impact on the tumor vascular system and the chemokine environment ( 138 ). Interestingly, as mentioned above, the microbiota plays an important role in the immune microenvironment of PC.…”

Section: Implications Of the Microbiota In The Treatment Of Pcmentioning

confidence: 99%

Association of the Microbiota and Pancreatic Cancer: Opportunities and Limitations

et al. 2022

View full text Add to dashboard Cite

The human body is thoroughly colonized by a wide variety of microorganisms, termed microbiota. Pancreatic cancer, one of the most aggressive forms of cancer, is no exception. The microbiota of pancreatic cancer largely influences and even dominates the occurrence, development and outcome of pancreatic cancer in many ways. Studies have shown that microbiota could change the malignant phenotype and prognosis of pancreatic cancer by stimulating persistent inflammation, regulating the antitumor immune system, changing the tumor microenvironment and affecting cellular metabolism. This is why the association of the microbiota with pancreatic cancer is an emerging area of research that warrants further exploration. Herein, we investigated the potential microbial markers of pancreatic cancer, related research models, the mechanism of action of microbiota in pancreatic cancer, and pancreatic cancer-microbiota-related treatment.

show abstract

RETRACTION: Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial

Cited by 56 publications

References 32 publications

Bibliometric Analysis of the Top-Cited Publications and Research Trends for Stereotactic Body Radiotherapy

Bibliometric Analysis of the Top-Cited Publications and Research Trends for Stereotactic Body Radiotherapy

Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment

Association of the Microbiota and Pancreatic Cancer: Opportunities and Limitations

Contact Info

Product

Resources

About